The family of human angiopoietins comprises factors with important roles in vascular development and angiogenesis. All angiopoietins bind with similar affinity to the endothelial cell-specific receptor, Tie2. The mechanism by which they contribute to angiogenesis is thought to involve regulation of endothelial cell interactions with supporting perivascular cells. In this study the genomic structures of all three human angiopoietins were characterised by direct sequencing of human genomic DNA from the appropriate P1 artificial chromosome (PAC) clones. The exact positions at the intron/exon boundaries and the lengths of all eight introns were determined. As would be expected from the homology of these three proteins, the positions of the introns in the three genes are highly conserved. The putative RNA transcription start site for each angiopoietin gene was also determined. Intron-specific primers were used to amplify each exon of angiopoietin-1 and angiopoietin-2 from individual genomic DNAs. Although no polymorphism has been detected in the coding region of angiopoietin-1, three independent polymorphisms have been identified for angiopoietin-2.   

1.
Ahmad SA, Jung YD, Fan F, Wilson M, Reinmuth N, Shaheen RM, Bucana CD, Ellis LM: The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 61:1255–1259 (2001).
2.
Audero E, Cascone I, Zanon I, Previtali SC, Piva R, Schiffer D, Bussolino F: Expression of angiopoietin-1 in human glioblastomas regulates tumour-induced angiogenesis: in vivo and in vitro studies. Arterioscler Thromb Vasc Biol 21:536–541 (2001).
3.
Cheung AH, Stewart RJ, Marsden PA: Endothelial Tie2/Tek ligands angiopoietin-1 (ANGPT1) and angiopoietin-2 (ANGPT2): regional localisation of the human genes to 8q22.3→q23 and 8p23. Genomics 48:389–391 (1998).
4.
Davis S, Aldrich TH, Jones PF, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion-trap expression cloning. Cell 87:1161–1169 (1996).
5.
de Souza SJ, Long M, Gilbert W: Introns and gene evolution. Genes Cells 1:493–505 (1996).
6.
Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M: Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61:2145–2153 (2001).
7.
Fryxell KJ: The coevolution of gene family trees. Trends Genet 12:364–369 (1996).
8.
Grosios K, Leek JP, Markham AF, Yancopoulos GD, Jones PF: Assignment of Angiopoietin 4, 1 and 2 to human chromosome band(s) 20p13.3, 8q22.3→23 and 8p23.1, respectively by in situ hybridization and radiation hybrid mapping. Cytogenet Cell Genet 84:118–120 (1999).
9.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Suri C, Hooper A, Friedlander DR, Grumet M, Zagzag D, Yancopoulos GD, Wiegand SJ: A new model of tumour angiogenesis: Dynamic balance between vascular growth and regression mediated by angiopoietins and VEGF. Science 284:1994–1998 (1999).
10.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel co-option, regression and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998 (1997).
11.
Huang YQ, Li JJ, Karpatkin S: Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 95:1993–1999 (2000).
12.
Jones, PF, McClain, J, Robinson, DM, Sato, TN, Yancopoulos, GD: Identification and characterisation of the chicken cDNAs encoding the endothelial cell-specific receptor tyrosine kinase Tie2 and its ligands, the angiopoietins. Angiogenesis 2:357–364 (1999).
13.
Kim I, Kim JH, Ryu YS, Jung SH, Nah JJ, Koh GY: Characterisation and expression of a novel alternatively spliced human angiopoietin-2. J biol Chem 275:18550–18556 (2000).
14.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton DL, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277:55–60 (1997).
15.
Mezquita J, Mezquita P, Montserrat P, Mezquita B, Francone V, Vilagrasa X, Mezquita C: Genomic structure and alternative splicing of chicken angiopoietin-2. Biochem Biophysical Res Comm 275:643–651 (2000).
16.
Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucl Acids Res 17:2503–2516 (1989).
17.
Procopio WN, Pelavin PI, Lee WMF, Yeilding NM: Angiopoietin-1 and –2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J biol Chem 274:30196–30201 (1999).
18.
Robberson BL, Cote GJ, Berget SM: Exon definition may facilitate splice site selection in RNAs with multiple exons. Mol Cell Biol 10:84–94 (1990).
19.
Sambrook J, Fritsch EF, Maniatis, T: Molecular Cloning: A Laboratory Manual, 2nd ed (Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
20.
Shapiro MB, Senapathy P: RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucl Acids Res 15:7155–7174 (1987).
21.
Stratman A, Acker T, Burger AM, Amann K, Risau W, Plate KH: Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growh factor receptor-2 dominant-negative receptor mutants. Int J Cancer 91:273–282 (2001).
22.
Stratman A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459–1466 (1998).
23.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 87:1171–1180 (1996).
24.
Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato T, Yancopoulos GD: Increased vascularisation in mice overexpressing angiopoietin 1. Science 282:468–471 (1998).
25.
Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, Kotake Y, Konishi Y: Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small lung carcinomas. Clin Cancer Res 5:2506–2510 (1999).
26.
Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341–345 (1999).
27.
Valenzuela DM, Griffiths J, Rojas J, Aldrich TH, Jones PF, Zhou H, McClain J, Copeland NG, Gilbert DJ, Jenkins NA, Papadopoulos N, Maisonpierre PC, Davis S, Yancopoulos GD: Angiopoietin 3 and 4: Diverging gene counterparts in mouse and man. Proc natl Acad Sci, USA 96:1904–1909 (1999).
28.
Yu L, Heere-Ress E, Boucher B, Defesche JC, Kastelein J, Lavoie MA, Genest J Jr: Familial hypercholesterolemia. Acceptor splice site (G-C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R (Honduras-1) (LDL-R1061 [-1] G-C). Atherosclerosis 146:125–131 (1999).
29.
Yu Q, Stamenkovic I: Angiopoietin-2 is implicated in the regulation of tumour angiogenesis. Am J Pathol 158:563–570 (2001).
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.